Literature DB >> 18470717

Procalcitonin for differential diagnosis of graft rejection and infection in patients with heart and/or lung grafts.

S Hammer1, F Meisner, P Dirschedl, P Fraunberger, B Meiser, B Reichart, C Hammer.   

Abstract

OBJECTIVES: Investigation of the reliability of Procalcitonin (PCT) for differential diagnosis of acute rejections and non-viral infections in heart and lung transplanted patients.
DESIGN: Retrospective study.
SETTING: Transplant intensive care unit (ICU) at a university hospital. PATIENTS: 57 heart, 18 lung and 3 heart-lung transplant patients. MEASUREMENTS: PCT was measured in plasma samples of heart and lung transplanted patients using a commercial immuno-luminescence assay and was compared with values of C-reactive protein (CRP) and leukocytes (WBC).
RESULTS: PCT was elevated in patients suffering from bacterial and fungal infections. The magnitude of values was clearly associated with the severity of the infection. Rejections and viral infections did not interfere with the PCT release.
CONCLUSION: PCT is a reliable predictor with discriminating power for non-viral systemic infections in patients after heart and/or lung transplantation. PCT allows an early differential diagnosis between rejection (AR) and bacterial/fungal infection (IF) and thus a rapid and focused therapeutic intervention. It avoids unnecessary antibiotic treatment which could be toxic for the graft itself in patients with rejection only. PCT provides vital information early to clinicians and allows them to improve the management of bacterial/fungal infections in immunocompromized transplant patients. PCT thus facilitates and improves the outcome of survival rate and the quality of life in the postoperative period of patients with heart and/or lung grafts.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 18470717      PMCID: PMC7095472          DOI: 10.1007/BF02900735

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  17 in total

1.  Procalcitonin as a marker of bacterial sepsis in patients infected with HIV-1.

Authors:  Y Gérard; D Hober; M Assicot; S Alfandari; F Ajana; J M Bourez; C Chidiac; Y Mouton; C Bohuon; P Wattre
Journal:  J Infect       Date:  1997-07       Impact factor: 6.072

2.  A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation.

Authors:  M E Billingham; N R Cary; M E Hammond; J Kemnitz; C Marboe; H A McCallister; D C Snovar; G L Winters; A Zerbe
Journal:  J Heart Transplant       Date:  1990 Nov-Dec

3.  Measurement of procalcitonin levels in children with bacterial or viral meningitis.

Authors:  D Gendrel; J Raymond; M Assicot; F Moulin; J L Iniguez; P Lebon; C Bohuon
Journal:  Clin Infect Dis       Date:  1997-06       Impact factor: 9.079

4.  Procalcitonin: a new marker for differential diagnosis of acute rejection and bacterial infection in heart transplantation.

Authors:  M Staehler; C Hammer; B Meiser; B Reichart
Journal:  Transplant Proc       Date:  1997 Feb-Mar       Impact factor: 1.066

5.  Serial transvenous biopsy of the transplanted human heart. Improved management of acute rejection episodes.

Authors:  P K Caves; E B Stinson; M E Billingham; N E Shumway
Journal:  Lancet       Date:  1974-05-04       Impact factor: 79.321

6.  Cytokine and cytokine-receptor profiles after liver and heart transplantation.

Authors:  P Fraunberger; M Pfeiffer; M Haller; R M Hoffmann; F M Zwiebel; P Uberfuhr; K W Jauch; D Nagel; A K Walli; D Seidel
Journal:  Transplant Proc       Date:  1995-06       Impact factor: 1.066

7.  High serum procalcitonin level in a 4-year-old liver transplant recipient with a disseminated candidiasis.

Authors:  Y Gérard; D Hober; S Petitjean; M Assicot; C Bohuon; Y Mouton; P Wattré
Journal:  Infection       Date:  1995 Sep-Oct       Impact factor: 3.553

8.  Persistent cytomegalovirus in liver allografts with chronic rejection.

Authors:  I Lautenschlager; K Höckerstedt; H Jalanko; R Loginov; K Salmela; E Taskinen; J Ahonen
Journal:  Hepatology       Date:  1997-01       Impact factor: 17.425

9.  Procalcitonin increase after endotoxin injection in normal subjects.

Authors:  P Dandona; D Nix; M F Wilson; A Aljada; J Love; M Assicot; C Bohuon
Journal:  J Clin Endocrinol Metab       Date:  1994-12       Impact factor: 5.958

Review 10.  Procalcitonin--a new indicator of the systemic response to severe infections.

Authors:  W Karzai; M Oberhoffer; A Meier-Hellmann; K Reinhart
Journal:  Infection       Date:  1997 Nov-Dec       Impact factor: 3.553

View more
  10 in total

Review 1.  Meta-analysis and systematic review of procalcitonin-guided therapy in respiratory tract infections.

Authors:  Hui Li; Yi-Feng Luo; Timothy S Blackwell; Can-Mao Xie
Journal:  Antimicrob Agents Chemother       Date:  2011-09-26       Impact factor: 5.191

2.  Procalcitonin: diagnostic value in systemic infections in chronic kidney disease or renal transplant patients.

Authors:  Raluca Dumea; Dimitrie Siriopol; Simona Hogas; Irina Mititiuc; Adrian Covic
Journal:  Int Urol Nephrol       Date:  2013-08-30       Impact factor: 2.370

Review 3.  [Biomarker for diagnosis of rejection after heart transplantation].

Authors:  Matthias Frick; Herwig Antretter; Otmar Pachinger; Gerhard Pölzl
Journal:  Herz       Date:  2010-01       Impact factor: 1.443

Review 4.  Where, when and how much: regulation of myelin proteolipid protein gene expression.

Authors:  P A Wight; A Dobretsova
Journal:  Cell Mol Life Sci       Date:  2004-04       Impact factor: 9.261

Review 5.  Cell-free DNA in the surveillance of heart transplant rejection.

Authors:  Dhruva Sharma; Ganapathy Subramaniam; Neha Sharma; Preksha Sharma
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2021-02-02

Review 6.  Diagnostic value and prognostic implications of serum procalcitonin after cardiac surgery: a systematic review of the literature.

Authors:  Christoph Sponholz; Yasser Sakr; Konrad Reinhart; Frank Brunkhorst
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

7.  Delta Neutrophil Index as a Marker for Differential Diagnosis between Acute Graft Pyelonephritis and Acute Graft Rejection.

Authors:  Dong Ho Shin; Eun Jung Kim; Soo Jin Kim; Ji-Young Park; Jieun Oh
Journal:  PLoS One       Date:  2015-08-14       Impact factor: 3.240

8.  Role of biomarkers in early infectious complications after lung transplantation.

Authors:  Borja Suberviola; Luzdivina Rellan; Jordi Riera; Reyes Iranzo; Ascension Garcia Campos; Juan Carlos Robles; Rosario Vicente; Eduardo Miñambres; Miguel Santibanez
Journal:  PLoS One       Date:  2017-07-13       Impact factor: 3.240

9.  Cell-free DNA donor fraction analysis in pediatric and adult heart transplant patients by multiplexed allele-specific quantitative PCR: Validation of a rapid and highly sensitive clinical test for stratification of rejection probability.

Authors:  Paula E North; Emily Ziegler; Donna K Mahnke; Karl D Stamm; Angela Thomm; Paul Daft; Mary Goetsch; Huan Ling Liang; Maria Angeles Baker; Adam Vepraskas; Chris Rosenau; Mahua Dasgupta; Pippa Simpson; Michael E Mitchell; Aoy Tomita-Mitchell
Journal:  PLoS One       Date:  2020-01-13       Impact factor: 3.240

10.  Usefulness of serum procalcitonin as a diagnostic biomarker of infection in children with chronic kidney disease.

Authors:  Fatina I Fadel; Manal F Elshamaa; Eman A Elghoroury; Ahmed M Badr; Solaf Kamel; Marwa M El-Sonbaty; Mona Raafat; Hebatallh Farouk
Journal:  Arch Med Sci Atheroscler Dis       Date:  2016-05-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.